Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12513930 | 0.92 | GAA (0.53) | GAATHRBLMNAHCN4PRMT5 | |
| SCHEMBL12437499 | 0.84 | TP53 (0.54) | GAALMNAPRMT5WDR77KDM4E | |
| SCHEMBL12437367 | 0.84 | CYP2C19 (0.57) | PRMT5WDR77KDM4E | |
| SCHEMBL12437441 | 0.83 | PRMT5 (0.50) | THRBPRMT5WDR77 | |
| SCHEMBL12437392 | 0.83 | KDM4E (0.55) | GAAPRMT5WDR77KDM4E | |
| SCHEMBL12437846 | 0.83 | THRB (0.55) | THRBLMNAHCN4TDP1 | |
| SCHEMBL12437481 | 0.81 | ROCK2 (0.48) | PRMT5WDR77 | |
| SCHEMBL12437374 | 0.81 | SLC5A7 (0.53) | — | |
| SCHEMBL12437436 | 0.81 | SLC5A7 (0.53) | — | |
| SCHEMBL12437468 | 0.79 | SLC5A7 (0.51) | LMNATDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| WO-2007098086-A2 | HYDROXYPIPERIDINE DERIVATIVES AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | GAA 487/4885THRB 3280/4885LMNA 2809/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | GAA 487/4885THRB 3280/4885LMNA 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.